A number of recent studies have focused on COVID-19 vaccine efficacy, hospitalization trends and variants.
Here are 15 findings from studies published since March 3:
- Pfizer said March 11 that its COVID-19 vaccine prevented 94 percent of asymptomatic cases.
- Novavax’s COVID-19 vaccine candidate was 96.4 percent effective in preventing COVID- 19 in its phase 3 K. trial.
- Eli Lilly said March 10 its COVID-19 antibody cocktail reduced the risk of hospitalization and death by 87 percent during a recent phase 3.
- GlaxoSmithKline and Vir Biotechnology said March 10 that their COVID-19 antibody drug was 85 percent effective at reducing virus-related hospitalizations and death in a phase 3 clinical trial.
- Despite few hospitalized COVID-19 patients having a bacterial infection, 52 percent of hospitalizations led to at least one antibiotic prescription, according to the Pew Charitable Trusts’ Antibiotic Resistance Project published March 10.
- People who have more than five symptoms of COVID-19 during the first week of illness may be more likely to develop prolonged health issues, known as “long COVID-19,” according to a study published March 10 in Nature
- Patients ages 30 and older infected with the K. coronavirus variant had a 64 percent higher death risk than those infected with previously circulating strains, according to a U.K. study published March 10 in The BMJ.
- People who received both doses of Pfizer-BioNTech’s messenger RNA vaccine and had no symptoms had an 80 percent lower risk of testing positive for COVID-19 compared to those who were unvaccinated, according to research published March 10 in Clinical Infectious The findings suggest mRNA vaccines are effective at reducing the risk of asymptomatic infection.
- Among 71,491 S. adults who were hospitalized with COVID-19, 27.8 percent were overweight and 50.2 percent were obese, according to the CDC’s latest Morbidity and Mortality Weekly Report published March 8.
- Just 0.025 percent of staff from Massachusetts General Hospital and Brigham and Women’s Hospital experienced anaphylaxis after receiving Pfizer or Moderna COVID-19 vaccines, according to a study published March 8 in JAMA.
- The COVID-19 vaccine developed by Pfizer and BioNTech was shown to be 95 percent effective in neutralizing a more contagious variant of the novel coronavirus that was discovered in Brazil, according to a study published March 8 in the New England Journal of Medicine.
- Both Pfizer’s and Moderna’s COVID-19 vaccines were at least 10 times less effective against a virus variant first found in South Africa in a small study conducted by researchers from Columbia University, Business Insider reported March 8.
- In-hospital mortality for COVID-19 patients fell 15 percentage points from March to August 2020, according to a study published March 5 in JAMA Network Open.
- Among 152 children hospitalized with COVID-19, 18, or 12 percent, developed acute kidney injury, according to a study published March 3 in Kidney International.
- The SARS-CoV-2 virus may more easily bind to the airway cells of people with Type A blood, according to a study published March 3 in Blood Advances.